bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinic...
May 17 2017 - 5:00PM
Business Wire
–Presentation will include safety and efficacy
data from 18 patients with up to 12 months of follow-up–
–Company to host event with live webcast,
Monday, June 5, 6:30 p.m. CT–
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company
committed to developing potentially transformative gene therapies
for severe genetic diseases and T cell-based immunotherapies for
cancer, announced that updated interim data from its study of
bb2121, the company’s anti-BCMA CAR T cell therapy will be
presented at the American Society of Clinical Oncology (ASCO)
Annual Meeting in Chicago, Illinois. bb2121 is currently being
studied in a Phase 1 trial in patients with relapsed/refractory
multiple myeloma.
“This past November we presented the initial clinical data from
the first three dosing cohorts in this ongoing Phase 1 study of
bb2121 in patients with relapsed/refractory multiple myeloma. At
ASCO in June, we look forward to presenting data on those same
patients with longer follow-up, as well as safety and efficacy data
on an additional 9 patients treated subsequently.” said David
Davidson, M.D., chief medical officer, bluebird bio. “These data
will advance our understanding of the bb2121 risk-benefit profile
and inform planning with our partners at Celgene for the dose
expansion cohort of this study, and the design of a potential
pivotal study.”
First-in-Human Multicenter Study of bb2121 anti-BCMA CAR T
Cell Therapy for Relapsed/Refractory Multiple Myeloma: Updated
Results (Abstract #3010).
Presenter: Jesus G. Berdeja, M.D., Sarah Cannon Research
Institute and Tennessee Oncology, Nashville, TNDate: Monday,
June 5, 2017, 4:45-6:00 pm CT (poster discussion); 8:00-11:30 am
CTLocation: Hall D1Session Title: Poster Discussion
Session: Developmental Therapeutics—Immunotherapy
The event and live webcast will begin at 6:30 p.m. CT (7:30 p.m.
ET) on Monday, June 5. To access the live webcast, please visit the
“Events & Presentations” page within the Investors and Media
section of the bluebird bio website at
http://investor.bluebirdbio.com. Replays of the webcast will be
available on the bluebird bio website for 90 days following the
event.
About bluebird bio, Inc.With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing
capabilities, bluebird bio has built an integrated product platform
with broad potential application to severe genetic diseases and
cancer. bluebird bio’s gene therapy clinical programs include its
Lenti-D™ product candidate, currently in a Phase 2/3 study,
called the Starbeam Study, for the treatment of cerebral
adrenoleukodystrophy, and its LentiGlobin™ product candidate,
currently in four clinical studies for the treatment of
transfusion-dependent β-thalassemia, and severe sickle cell
disease. bluebird bio’s oncology pipeline is built upon the
company’s leadership in lentiviral gene delivery and T cell
engineering, with a focus on developing novel T cell-based
immunotherapies, including chimeric antigen receptor (CAR T) and T
cell receptor (TCR) therapies. bluebird bio’s lead oncology
program, bb2121, is an anti-BCMA CAR T program partnered
with Celgene. bb2121 is currently being studied in a Phase 1
trial for the treatment of relapsed/refractory multiple myeloma.
bluebird bio also has discovery research programs utilizing
megaTAL/homing endonuclease gene editing technologies with the
potential for use across the company’s pipeline.
bluebird bio has operations in Cambridge,
Massachusetts, Seattle, Washington and Europe.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the Company’s bb2121 product candidate to treat
relapsed/refractory multiple myeloma. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risk that our bb2121 product candidate will not be successfully
developed, approved or commercialized. For a discussion of other
risks and uncertainties, and other important factors, any of which
could cause our actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in our most recent Form 10-Q, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and bluebird bio undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170517006149/en/
Investors:bluebird bio, Inc.Manisha Pai,
617-245-2107mpai@bluebirdbio.comorMedia:bluebird bio, Inc.Elizabeth
Pingpank, 617-914-8736epingpank@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024